newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) announced that CEO Shaun Bagai & CFO Mark Voll will present at the Alliance Global Partners Annual Healthcare Company Showcase on May 20, 2026.
  • The presentation will cover record first-quarter 2026 revenue from RenovoCath, accelerating adoption at high-volume cancer centers, & growing repeat orders.
  • Management will highlight the Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine delivered via RenovoCath (IAG) in locally advanced pancreatic cancer.
  • RenovoRx expects to notify enrollment closure for the TIGeR-PaC trial in early June 2026, meeting the milestone to finish enrollment by end-of-June 2026.
  • Final data from the TIGeR-PaC trial is anticipated in mid to late 2027.
  • The company outlined ongoing support for investigator-initiated trials & post-marketing registry studies for borderline resectable & metastatic pancreatic cancer to broaden the TAMP therapy platform.
  • RenovoCath is an FDA-cleared device for isolating blood flow & delivering therapeutic agents to peripheral vascular sites, including temporary vessel occlusion.
  • In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with Q1 2026 sales reaching a record $563,000.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • The AGP virtual showcase is scheduled for 1:40 PM ET on May 20, 2026, with a webcast & 30-day replay available on the company's investor relations site.